Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - Medac

Drug Profile

Aminolevulinic acid - Medac

Alternative Names: 5-ALA - Medac; 5-ALA - Photonamic; 5-ALA Patch; ALA - Medac; ALA-HCl; Alacare; Aminolevulinic acid HCl; Aminolevulinic acid hydrochloride - Medac; Effala; Gleolan; Gliolan; PD L 506; PD P 506 A; PD P 506 A-PDT

Latest Information Update: 08 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Photonamic
  • Developer LINK Healthcare; Medac; Medexus Pharmaceuticals; NX Development Corp; Photonamic; Specialised Therapeutics Australia; Spirig Pharma
  • Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Glioma
  • Phase III Meningioma
  • Phase II Glioblastoma; Onychomycosis

Most Recent Events

  • 07 Apr 2023 NX Development Corp plans a phase III trial for Ovarian cancer (Recurrent, Newly diagnosed, First-line therapy) in July 2023 (PO)(NCT05804370)
  • 19 Sep 2022 Launched for Glioma (Diagnosis) in USA (PO)
  • 01 Mar 2022 Aminolevulinic acid licensed for marketing and distribution to Medexus Pharmaceuticals in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top